• Identifying Drug Development Opportunities for DMD with CureDuchenne

  • Aug 1 2024
  • Length: 30 mins
  • Podcast

Identifying Drug Development Opportunities for DMD with CureDuchenne

Listen for free

View show details

  • Summary

  • We love to hear from our listeners. Send us a message.

    Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dystrophy (DMD). Miller and Kelly also share their advice and recommendations for companies developing drugs for DMD - while much progress has been made, more innovation is needed.
    Show more Show less
Biological Sciences
Show more Show less

What listeners say about Identifying Drug Development Opportunities for DMD with CureDuchenne

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available